Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
- Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
- UCHealth Memorial Hospital Central — Colorado Springs, Colorado
- Memorial Hospital North — Colorado Springs, Colorado
- UCHealth Highlands Ranch Hospital — Highlands Ranch, Colorado
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
- Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
- UCHealth Memorial Hospital Central — Colorado Springs, Colorado
- Memorial Hospital North — Colorado Springs, Colorado
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Colorado: - University of Colorado Hospital — Aurora, Colorado
- Rocky Mountain Cancer Centers-Boulder — Boulder, Colorado
- UCHealth Memorial Hospital Central — Colorado Springs, Colorado
- Memorial Hospital North — Colorado Springs, Colorado
- Porter Adventist Hospital — Denver, Colorado
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Colorado: - Rocky Mountain Regional VA Medical Center — Aurora, Colorado
- Kaiser Permanente-Franklin — Denver, Colorado
- Shaw Cancer Center — Edwards, Colorado
- Saint Mary's Hospital and Regional Medical Center — Grand Junction, Colorado
- Kaiser Permanente-Rock Creek — Lafayette, Colorado
Phase 3 Recruiting Academic/Other
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
- UCHealth Memorial Hospital Central — Colorado Springs, Colorado
- Memorial Hospital North — Colorado Springs, Colorado
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Colorado: - AdventHealth Medical Group Urology of Denver — Denver, Colorado
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Colorado: - Rocky Mountain Cancer Centers — Aurora, Colorado
- AdventHealth Porter Oncology Research — Denver, Colorado
- Vail Health Shaw Cancer Center — Edwards, Colorado
- Grand Valley Oncology — Grand Junction, Colorado
- Colorado Clinical Research — Lakewood, Colorado
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Colorado: - Rocky Mountain Cancer Centers — Aurora, Colorado
- University of Colorado Cancer Center — Aurora, Colorado
- Colorado Clinical Research — Lakewood, Colorado
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in Colorado: - Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0053) — Aurora, Colorado
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Colorado: - Anschutz Cancer Pavilion ( Site 0046) — Aurora, Colorado
- University of Colorado Health - Highlands Ranch Hospital ( Site 0111) — Highlands Ranch, Colorado
- Colorado Clinical Research ( Site 0067) — Lakewood, Colorado
- University of Colorado Health - Lone Tree Medical Center ( Site 0112) — Lone Tree, Colorado
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Sites in Colorado: - Rocky Mountain Cancer Centers — Denver, Colorado
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Colorado: - Research Site — Lakewood, Colorado
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in Colorado: - Rocky Mountain Cancer Centers — Denver, Colorado
Phase 3 Recruiting Industry
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicine…
Sponsor: BioNTech SE
NCT ID: NCT07365995
Sites in Colorado: - Rocky Mountain Cancer Centers — Aurora, Colorado
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Colorado: - UCHealth Memorial Hospital Central — Colorado Springs, Colorado
- Memorial Hospital North — Colorado Springs, Colorado
- Poudre Valley Hospital — Fort Collins, Colorado
- Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
- UCHealth Greeley Hospital — Greeley, Colorado
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Colorado: - Sarah Cannon Research Institute (SCRI) — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06800313
Sites in Colorado: - Rocky Mountain Cancer Center — Colorado Springs, Colorado
- Sarah Cannon Research Institute 1 — Denver, Colorado
Phase 2 Recruiting Industry
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on…
Sponsor: Zenith Epigenetics
NCT ID: NCT04986423
Sites in Colorado: - Colorado Urology — Lakewood, Colorado
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a m…
Sponsor: Phanes Therapeutics
NCT ID: NCT05652686
Sites in Colorado: - Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Phase 2 Recruiting Industry
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation t…
Sponsor: Candel Therapeutics, Inc.
NCT ID: NCT07332000
Sites in Colorado: - Colorado Clinical Research — Lakewood, Colorado
- Urology Associates — Littleton, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
NCT ID: NCT06239194
Sites in Colorado: - Sarah Cannon Research Institute — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expan…
Sponsor: GlaxoSmithKline
NCT ID: NCT06990880
Sites in Colorado: - GSK Investigational Site — Denver, Colorado
Phase 2 Recruiting Academic/Other
This study investigates the efficacy of a telehealth exercise program designed specifically for rural cancer survivors with cancer-related fatigue (CRF). Small dried blood samples and measures of physical function will be collected through…
Sponsor: University of Colorado, Denver
NCT ID: NCT07001241
Sites in Colorado: - University of Colorado Anschutz Medical Campus — Aurora, Colorado
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Colorado: - Exelixis Clinical Site #87 — Littleton, Colorado
Phase 1 Recruiting Industry
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
Sponsor: SystImmune Inc.
NCT ID: NCT07080242
Sites in Colorado: - University of Colorado - Anschutz Cancer Pavilion — Aurora, Colorado